Cargando…

Recombinant Pseudomonas exotoxin produced by cloning of Pseudomonas aeruginosa DNA in Escherichia coli having low toxicity to human or mice cells but retaining enzymatic activity giving cell-specific immunotoxin; vaccine application

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 1988
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131181/
http://dx.doi.org/10.1016/0264-410X(88)90231-9
_version_ 1783517180266020864
collection PubMed
description
format Online
Article
Text
id pubmed-7131181
institution National Center for Biotechnology Information
language English
publishDate 1988
publisher Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71311812020-04-08 Recombinant Pseudomonas exotoxin produced by cloning of Pseudomonas aeruginosa DNA in Escherichia coli having low toxicity to human or mice cells but retaining enzymatic activity giving cell-specific immunotoxin; vaccine application Vaccine Patent Report Published by Elsevier Ltd. 1988-06 2002-11-13 /pmc/articles/PMC7131181/ http://dx.doi.org/10.1016/0264-410X(88)90231-9 Text en © 1988 Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Patent Report
Recombinant Pseudomonas exotoxin produced by cloning of Pseudomonas aeruginosa DNA in Escherichia coli having low toxicity to human or mice cells but retaining enzymatic activity giving cell-specific immunotoxin; vaccine application
title Recombinant Pseudomonas exotoxin produced by cloning of Pseudomonas aeruginosa DNA in Escherichia coli having low toxicity to human or mice cells but retaining enzymatic activity giving cell-specific immunotoxin; vaccine application
title_full Recombinant Pseudomonas exotoxin produced by cloning of Pseudomonas aeruginosa DNA in Escherichia coli having low toxicity to human or mice cells but retaining enzymatic activity giving cell-specific immunotoxin; vaccine application
title_fullStr Recombinant Pseudomonas exotoxin produced by cloning of Pseudomonas aeruginosa DNA in Escherichia coli having low toxicity to human or mice cells but retaining enzymatic activity giving cell-specific immunotoxin; vaccine application
title_full_unstemmed Recombinant Pseudomonas exotoxin produced by cloning of Pseudomonas aeruginosa DNA in Escherichia coli having low toxicity to human or mice cells but retaining enzymatic activity giving cell-specific immunotoxin; vaccine application
title_short Recombinant Pseudomonas exotoxin produced by cloning of Pseudomonas aeruginosa DNA in Escherichia coli having low toxicity to human or mice cells but retaining enzymatic activity giving cell-specific immunotoxin; vaccine application
title_sort recombinant pseudomonas exotoxin produced by cloning of pseudomonas aeruginosa dna in escherichia coli having low toxicity to human or mice cells but retaining enzymatic activity giving cell-specific immunotoxin; vaccine application
topic Patent Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131181/
http://dx.doi.org/10.1016/0264-410X(88)90231-9